Pleomorphous leiomyosarcoma of the mesocolon: a case report

Saad Rifki Jai1, Robleh Hassan Farah1-8, Brahim Hamdaoui1, Rachid Boubettal1, Farid Chehab1

1Service de Chirurgie Viscérale Aile 3, Centre Hospitalier Universitaire Ibn Rochd, Université Hassan II, Casablanca, Maroc

8Corresponding author: Robleh Hassan Farah, Service de Chirurgie Viscérale Aile 3, Centre Hospitalier Universitaire Ibn Rochd, Université Hassan II, Casablanca, Maroc

Key words: Pleomorphous leiomyosarcoma, mesocolon, smooth muscle tumors

Received: 27/09/2015 - Accepted: 05/11/2015 - Published: 02/12/2015

Abstract
Leiomyosarcoma is a rare tumor of the smooth muscle, but relatively frequent in the stomach and the small intestine. The mesocolic site is rare. Globally, leiomyosarcoma represents less than 0, 1% of the malignant tumors found in the colon and the anus. Because of the similarities with other digestive tumors, namely mesenchymatous or benign tumors of the smooth muscle, the diagnosis of a pleomorphic sarcoma remains difficult even at the histological stage. Surgery is the mainstay of the therapy. We report a case of leiomyosarcoma of the mesocolon and discuss about its main characteristics in the view of the current literature about this pathological condition.

Pan African Medical Journal. 2015; 22:322 doi:10.11604/pamj.2015.22.322.8050

This article is available online at: http://www.panafrican-med-journal.com/content/article/22/322/full/

© Saad Rifki Jai et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Soft tissue sarcomas (STS) are an extremely diverse group of tumors occurring in every region of the human body and affecting all ages with significant morbidity and mortality. Soft tissue sarcomas include more than 35 different neoplasms derived from fat, muscle, nerve, fibrous, vascular, or deep skin tissue, and can be classified by their tissue of origin or their anatomical location [1]. The World Health Organization classifies liposarcomas into 5 histologic subtypes: well-differentiated, dedifferentiated, myxoid, round cell, and pleomorphic sarcomas. Dedifferentiated histologic subtypes have a worse prognosis and an increased risk of local recurrence compared with well-differentiated liposarcomas [2]. Therefore, aggressive complete surgical resection of the tumor and adjacent organs is the mainstay of treatment for dedifferentiated liposarcomas [2]. We report here a case of pleomorphic leiomyosarcoma arising from the mesocolon and discuss its main characteristics and the management of this tumor along with a review of the literature.

Patient and observation

A 62-year-old female patient, who had past medical history of well treated pulmonary tuberculosis 6 years ago, that hospitalized because of a chronic abdominal pain for 10 months. The patient reported weight loss about 6 kg during her illness. The physical examination found palpable per-umbilical mass (10 cm of diameter), hard and mobile relatively to the deeper and superficial neighboring structures. No lymph node or ascites was found. Laboratory exams: complete blood count was in normal range and tumor markers were negative.

Computer tomography scanning of the abdomen showed a round tissular mass with irregular edges, which makes 14 cm in its great axis, with central necrotic areas enhancement in the peripheral zones (Figure 1). A primitive pelvic tumor was suspected. At laparotomy exploration, the surgeons noted a pink multiloblar tumor of the transverse mesocolon of 15 cm is his greatest axis, without any ascites or peritoneal carcinoid. The surgeons performed a resection of the tumor and the adjacent part of the mesocolon (Figure 2).

On macroscopically exam, the tumor was 15 cm of diameter, firm with necrotic areas. Histopathological examination combined with immunohistochemical studies established the diagnosis of pleomorphic sarcoma of the mesocolon. The postoperative course was uneventful. No adjuvant therapy was instituted.

Discussion

Pleomorphic sarcomas represent approximately 10 to 15% of the sarcoma of the smooth tissues of the adult [3]. The mean age at occurrence is about the 6th decade of the life [4]. There is a slight male predominance, with a sex ratio of 1.6 [5,6].

The clinical symptomatology is not specific; can be abdominal pain or mass [7-9], alteration in the general condition [10, 11], or signs related to a vascular or nervous compression [10] can all be experienced by the patient. Hepatic and pulmonary metastasis can be observed in the course of a leiomyosarcoma of the mesocolon. They represented the main causes of the death. Involvement of the nodes is rare [10]; ultrasonography and computer tomographic scanning of the abdomen are very helpful in view of the diagnosis of leiomyosarcoma. Leiomysarcoma usually appears at ultrasonography as a high volume and irregular mass with multiples echogenic lobes, and central cavity of necrotic areas. Computer tomography scanning also exhibits a rounded in homogenous tissular mass with irregular edges, central necrotic areas and enhancement of the peripheral zone.

Pathological exam combined with immunohistochemical studies usually confirms the diagnosis of pleomorphic sarcomas are defined as mesenchymal tumors consisting on pleomorphic spindle-cells with different forms and size and the pleomorphic is high lightened by the nuclear atypical and the anyso caryopses [3].

During the years 1980 [3], a balanced proposition of pleomorphic sarcoma was classified as malignant histocytofibromas (MHF). Currently, the MHF is no way considered as a specific clinic pathologic entity but just as a morphological feature seen in many tumors, including melanomas, lymphomas and carcinomas. Because of the progress in immunohistochemistry and electronic microscopy, some criteria's have been included in order to make a subclassification of the pleomorphic sarcoma entity.
Macroscopically, pleomorphic sarcoma presents as a white to grey-pinked hard and firm great mass, sometimes elastic or renittent. More it is more than 10 cm, the tumor is generally lobulated with smooth areas corresponding to intratumoral necrotic zones, and recovered by a complex channel of blood vessels.

At the microscopic level, pleomorphic leiomyosarcoma contain pleomorphic cells, which are around and spindle shaped, extending as longs fasciles takings contact the ones to others in rights angles. Atypical cells are frequent because of the presence of giants cells, normal and abnormal mitosis. The cells have an abundant eosinophil and fibrillary cytoplasm. The nucleus muscle and desmine (50 to 70% of all the cases) [3].

The differential diagnosis is essentially with others clinical entities such as undifferenciated pleomorphic sarcoma, gastro-intestinal tumors of the stroma, pleomorphic rhabdomyosarcoma. Immunohistochemistry studies allow performing the diagnosis [3].

The benign or malignant nature of a pleomorphic sarcoma is not always easy to establish. Grading's system relying on histological parameters that have been described in order to better differentiate between the different tumoral grades and so the prognosis [12]. Like for the other sarcoma of the smooth tissues, prognostic factors on the histological type, the depth of the tumor, the high grade, the tumor size (more than 5cm), tumor necrosis great mitotic activity, infiltration in the neighboring structures, vascular invasion and the localization other than a limb, recurrence. Generally pleomorphic leiomyosarcoma are considered as very aggressive and metastatic pleomorphic sarcomas.

Moreover, it has been shown that myogenic differentiation was a deleterious prognostic factors [13]. The treatment of pleomorphic sarcomas rely on surgery. The excision of the tumor in a monobloc fashion, with the viscera and without any tumoral effraction, is the standard of therapy [7]. Nodes excision is not systematic because involvement or recurrences at these sites are rare [8]. The high recurrence rate after surgery has led to investigations into the use of combined modality treatment for these tumours. As the most common form of relapse in retroperitoneal sarcoma is a local recurrence, adjuvant radiotherapy has been proposed to enhance the cure rates and improve the relapse free survival. Studies in extremity sarcomas have demonstrated improved local control rates when surgery was combined with radiotherapy. Globally, the sensitivity of sarcomas to irradiation is low [14]. However, there is no consensus regarding use of neoadjuvant or adjuvant chemotherapy. Neo adjuvant chemotherapy (NACT) is given with an aim to improve the resectability of the tumour. The advantages of NACT are a reduction in the size of tumours, probability of a margin negative resection and determining the tumour response to chemotherapy. In addition, any micrometastatic disease could be controlled. The disadvantages are that a tumour may not respond to chemotherapy and a potentially resectable tumour may become inoperable. Chemotherapy may also worsen the performance status of the patient [14]. Several studies, most of them non-randomized have not shown any consistent benefit withNACT. In one large study, Meric et al, reported results of 65 patients of RPS with NACT doxorubicin or ifosfamide, of these 23 had resectable RPS [15]. After surgical treatment, the course of pleomorphic sarcoma is characterized by the high frequency of local recurrences, as up as 44% to 85% [7, 11]. The management of these recurrences relies on iterative surgeries. The global rate of survival at 5 years is about 20 to 30% [7, 11].

Conclusion

Pleomorphic leiomyosarcoma of the mesocolon is a rare tumor. The positive diagnosis of this condition can be made on pathological exam combined with immunohistochemistry studies after surgery. The association of an adjuvant therapy remains controversial; however, adjuvant chemotherapy can be suggested in the case of a bad prognosis, a short time after the surgical procedure.

Competing interests

The authors declare no competing interests.

Authors’ contributions

All authors are fully participated in the study design, performed the analysis, and wrote the manuscript. All authors read and approved the final manuscript.
**Figures**

Figure 1: CT scan of the abdomen showing a round tissular mass with irregular edges with central necrotic areas enhancement in the peripheral zones

Figure 2: Removed specimen of the tumor and the adjacent part of the mesocolon

**References**

1. Liles JS, Tzeng CW, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009 Jun;46(6):445-503. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

2. Takeda K, Aimoto T, Yoshioka M, Nakamura Y, Yamahatsu K, Ishiwata T, Naito Z, Miyashita M, Uchida E. Dedifferentiated liposarcoma arising from the mesocolon ascendens: report of a case. J Nippon Med Sch. 2012;79(5):385-90. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

3. Louis guillou MD. Pleiomorphous sarcoma: subclassification, myogenic differentiation and prognosis. Elsevier 2008; 529: 14-11. [Google Scholar](https://scholar.google.com)

4. Le Péchoux C, Bonvalot S, Le Cesne A, Roberti E, Vanel D, Terrier P, Missenard G, Habrand JL. Place and technical aspects of external beam radiation therapy in the treatment of adult soft tissue sarcomas. Cancer Radiother. 2006 Feb-Mar;10(1-2):50-62 Epub 2005 Dec 27. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

5. Shraibman S, French RJ. Giant leiomyosarcoma of the transverse mesocolon . Aust N Z J Surg. 1999 Oct;69(10):749-51. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

6. Xu YH, guo KG, guo RX , Ge CJ, Tian Yl , He SG. Surgical management of 143 patients with adult primary retroperitoneal tumors. World J Gastroenterol. 2007 May 14; 13(18): 2619-2621. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

7. Chen CQ, Yin L, Peng CH, Cai Y, Li YF, Zhao R, Zhou HJ, Li HW. Prognostic factors of retroperitoneal soft tissue sarcomas: analysis of 132 cases.Chin Med J (Engl). 2007 Jun 20; 120 (12):1047-50. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

8. Ben Hassouna J, Slimane M, Dmak , Chargui R, Ben Babouche W, Oukad M. Retroperitoneal sarcomas: a single center experience. Cancer Radiother. 2008 Sep;12 (5):331-5. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

9. Feig BW. Retroperitoneal sarcomas. Surg Oncol Clin N Am. 2003 Apr; 12 (2):369-77. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

10. Van Dam PA, Lowe DG, McKenzie-Gray B, Shepherd JH. Retroperitoneal soft tissue sarcomas: a review of the literature. Obstet Gynecol Surv. 1990 Oct;45(10):670-82. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

11. Liles JS, Tzeng CW, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009 Jun; 46(6):445-503. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

12. Hassan I, Park SZ, Donohue JH, Nagorney DM, Kay PA et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004 Feb; 239 (2):244-50. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

13. Sun X, Guo W, Shen JK, Mankin HJ, Hornicek FJ, Duan Z. 'Rhabdomyosarcoma: Advances in Molecular and Cellular Biology'. Sarcoma. 2015;2015:232010. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

14. Vijay Kumar, Sanjeev Misra , Arun Chaturvedi. Retroperitoneal Sarcomas- A Challenging Problem. Indian J Surg Oncol. September 2012; 3(3):215-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)

15. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, PlagerC, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 1;95 (5):1120-6. [PubMed](https://pubmed.ncbi.nlm.nih.gov/)[Google Scholar](https://scholar.google.com)
**Figure 1**: CT scan of the abdomen showing a round tissular mass with irregular edges with central necrotic areas enhancement in the peripheral zones.

**Figure 2**: Removed specimen of the tumor and the adjacent part of the mesecolon.